Viewing Study NCT03135951

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2026-03-10 @ 7:22 PM
Study NCT ID: NCT03135951
Status: COMPLETED
Last Update Posted: 2020-11-13
First Post: 2017-04-20
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy
Sponsor: Spectrum Pharmaceuticals, Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Pharmacokinetics View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Pharmacokinetics View
None Long-acting Myeloid Growth Factor View
None Early Stage Breast Cancer View
None Docetaxel + Cyclophosphamide (TC) Chemotherapy View